专利号:US-11285169-B2 优先权日:2013-03-13 标题 :Methods for modulating chemotherapeutic cytotoxicity 发明人:ROBERTS DAVID D; SOTO PANTOJA DAVID R 权利人:US HEALTH 摘要:Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.
1: Langmead CJ, Jerman JC, Brough SJ, Scott C, Porter RA, Herdon HJ. Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol. 2004 Jan;141(2):340-6. doi: 10.1038/sj.bjp.0705610. Epub 2003 Dec 22. 2: Tissen I, Kurbanov R, Hohlov K, Proshin S, Lebedev A, Bagaturiya G, Shabanov P. OX1R ANTAGONIST SB408124 ACTION AND EXTRAHYPOTHALAMIC CRF IN RATS AFTER PSYCHOTRAUMATIC EXPOSURE. Georgian Med News. 2019 May;(290):127-131. 7(7):e39131. doi: 10.1371/journal.pone.0039131. Epub 2012 Jul 2. 4: Valiante S, Liguori G, Tafuri S, Pavone LM, Campese R, Monaco R, Iachetta G, Assisi L, Mirabella N, Forte M, Costagliola A, Vittoria A. Expression and potential role of the peptide orexin-A in prostate cancer. Biochem Biophys Res Commun. 2015 Sep 4;464(4):1290-1296. doi: 10.1016/j.bbrc.2015.07.124. Epub 2015 Jul 26. 215(1):191-203. doi: 10.1007/s00213-010-2127-x. Epub 2010 Dec 22. 177(1-3):46-52. doi: 10.1016/j.regpep.2012.04.007. Epub 2012 May 2. 1864(11):3618-3628. doi: 10.1016/j.bbadis.2018.08.023. Epub 2018 Aug 18. 352(3):590-601. doi: 10.1124/jpet.114.220392. Epub 2015 Jan 12.
合成参考文献
参考文献:10.1016/j.neuroscience.2014.08.017 摘要:Choudhary RC, Khanday MA, Mitra A, Mallick BN. Perifornical orexinergic neurons modulate REM sleep by influencing locus coeruleus neurons in rats. Neuroscience. 2014 Oct 24;279():33–43. doi: 10.1016/j.neuroscience.2014.08.017. 参考文献:10.1007/s11906-018-0879-6 摘要:Sieminski M, Szypenbejl J, Partinen E. Orexins, Sleep, and Blood Pressure. Current Hypertension Reports. 2018 Jul 10;20(9):79. doi: 10.1007/s11906-018-0879-6. 参考文献:10.1124/mol.119.115964 摘要:Lee TD, Lee OW, Brimacombe KR, Chen L, Guha R, Lusvarghi S, Tebase BG, Klumpp-Thomas C, Robey RW, Ambudkar SV, Shen M, Gottesman MM, Hall MD. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology. 2019 Nov;96(5):629–40. doi: 10.1124/mol.119.115964. 参考文献:10.1007/978-3-031-07897-2_10 摘要:Fathima S, Murala S, Bollu PC. Orexins. 2022. In: Neurochemistry in Clinical Practice. 参考文献:10.1124/jpet.114.220392 摘要:Bonaventure P, Yun S, Johnson PL, Shekhar A, Fitz SD, Shireman BT, Lebold TP, Nepomuceno D, Lord B, Wennerholm M, Shelton J, Carruthers N, Lovenberg T, Dugovic C. A Selective Orexin-1 Receptor Antagonist Attenuates Stress-Induced Hyperarousal without Hypnotic Effects. The Journal of Pharmacology and Experimental Therapeutics. 2015 Mar;352(3):590–601. doi: 10.1124/jpet.114.220392.